Eli Lilly & Co.: Strategic Growth Driven by Mounjaro and Zepbound with Attractive Entry Point
Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...
‘Lilly’ Review: Equal-Pay Activist and Trailblazer Lilly Ledbetter Deserves a Much Better Film
Patricia Clarkson is forgettable in tonally confusing 'Lilly,' full of intrusively edited archival material and curious ...
wrtv3d
Lilly Endowment investing in Hoosier kids and families through Early Years Initiative
Early Learning Indiana is a nonprofit organization focused on making sure kids have the skills they need to thrive in kindergarten and beyond. 68 organizations recently joined the initiative.
Daily Journal3d
State’s big, bold LEAP District play draws some reflection
In the case of LEAP, however, the state is doing both. The IEDC and Lebanon officials have collectively pledged nearly $1.8 ...
Reporter.net7d
Growth topped the list of Boone County's top stories for 2024
Lebanon Mayor Matthew Gentry in autumn struck a deal with Citizen’s Energy Group to bring 25 million gallons per day to ...
The Times of Northwest Indiana12d
Lilly's NWI Thrive project aims to turn Gary and Michigan City into gateways for Indiana Dunes National Park
The project aims to attract more visitors to the Miller Woods, Paul H. Douglas Center for Environmental Education and Gary's Miller neighborhood on the west end of the park and the Mount Baldy Beach ...
ABC 7 Chicago17d
FDA approves Eli Lilly's obesity medication for obstructive sleep apnea
Eli Lilly estimates that is about 15-20 million adults in the U.S. Obstructive sleep apnea isnt just an inconvenience, its a serious medical condition that impairs breathing and sleep quality.
CNN17d
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli ... 1 drugs. Lilly’s Zepbound, approved in November 2023 as the Indiana ...
Seeking Alpha18d
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now
This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor. Clinical trial results from competitors were largely underwhelming, including this week’s ...
Daily Reporter19d
FDA says knockoff versions of Lilly obesity drug must come off the market
The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs that have become ...
The Motley Fool20d
Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout
On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase. For a seventh consecutive year, the company ...
Reuters20d
Eli Lilly's Alzheimer's treatment approved in China
Like Leqembi, Lilly's Kisunla is designed to clear an Alzheimer's-related protein called beta-amyloid from the brain. In a large, late-stage trial, Kisunla slowed the progression of memory and ...